2017
DOI: 10.3390/ijms18071385
|View full text |Cite
|
Sign up to set email alerts
|

Pharmacological Modulation of Radiation Damage. Does It Exist a Chance for Other Substances than Hematopoietic Growth Factors and Cytokines?

Abstract: In recent times, cytokines and hematopoietic growth factors have been at the center of attention for many researchers trying to establish pharmacological therapeutic procedures for the treatment of radiation accident victims. Two granulocyte colony-stimulating factor-based radiation countermeasures have been approved for the treatment of the hematopoietic acute radiation syndrome. However, at the same time, many different substances with varying effects have been tested in animal studies as potential radioprot… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
11
0

Year Published

2018
2018
2023
2023

Publication Types

Select...
10

Relationship

1
9

Authors

Journals

citations
Cited by 31 publications
(11 citation statements)
references
References 155 publications
(164 reference statements)
0
11
0
Order By: Relevance
“…In this technical sense, ideal radiomitigators ought to be anti-inflammatory, enhance antioxidant defenses, have antimutagenic properties, upregulate the DNA repair mechanisms, activate mitotic processes, cell growth and differentiation to promote the regeneration of damaged tissues, and forestall or reduce ARS and CRS. At present, no molecule under study meets all these prerequisites, but there are a large number of choices [ 54 , 233 , 234 ], which may be combined, for quick administration to affected individuals. For such situations, we may recommend the following:…”
Section: Medical Countermeasuresmentioning
confidence: 99%
“…In this technical sense, ideal radiomitigators ought to be anti-inflammatory, enhance antioxidant defenses, have antimutagenic properties, upregulate the DNA repair mechanisms, activate mitotic processes, cell growth and differentiation to promote the regeneration of damaged tissues, and forestall or reduce ARS and CRS. At present, no molecule under study meets all these prerequisites, but there are a large number of choices [ 54 , 233 , 234 ], which may be combined, for quick administration to affected individuals. For such situations, we may recommend the following:…”
Section: Medical Countermeasuresmentioning
confidence: 99%
“…Several promising strategies are continuously being developed to improve radiotherapy. For instance, spatial dose fractionation, time dose fractionation, micro/mini-beam irradiation, heavy-ion irradiation [10,11,12,13,14,15,16,17], and application of normal cell radio-protectants [18,19] and/or tumor cell radiosensitizers [20] could already be used in practice and eventually combined. One of the radiosensitizing approaches proposed is to selectively potentiate radiation toxicity for tumor cells by metal nanoparticles [21,22,23,24,25,26,27,28].…”
Section: Introductionmentioning
confidence: 99%
“…Therefore, there is an urgent need to examine the ideal prevention strategies which function to protect the entire ovarian milieu from radiation damage [12]. Some nonpharmacologic [13, 14] and pharmacologic strategies [15] have been tried in an attempt to ameliorate the gonadotoxic effect of irradiation. However, the ideal mitigation paradigm has not been discovered yet.…”
Section: Introductionmentioning
confidence: 99%